Recapturing Disease Response: A Phase 2 Study of Carfilzomib 56 mg/m2 in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Carfilzomib 27 mg/m2
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
0
Citations
NaN
KQI